Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma (NCT06182774)
A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration Versus Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop). Recent observations suggest that stopping daratumumab or isatuximb after about a year and a half of treatment may work just as well as giving them continuously with lenalidomide and dexamethasone. Sometimes, bortezomib is also given. This study is being done to answer the question: is less daratumumab or isatuximab treatment as good as more?
Who can join: Review the eligibility criteria below.
Location: Cross Cancer Institute — Edmonton, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- Cross Cancer Institute — Edmonton, Alberta
- BCCA - Kelowna — Kelowna, British Columbia
- BCCA - Vancouver — Vancouver, British Columbia
- CancerCare Manitoba — Winnipeg, Manitoba
- The Moncton Hospital — Moncton, New Brunswick
- Regional Health Authority B, Zone 2 — Saint John, New Brunswick
- Dr. H. Bliss Murphy Cancer Centre — St. John's, Newfoundland and Labrador
- Royal Victoria Regional Health Centre — Barrie, Ontario
- William Osler Health System — Brampton, Ontario
- Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Ontario
- Kingston Health Sciences Centre — Kingston, Ontario
- Waterloo Regional Health Network (WRHN) — Kitchener, Ontario
- London Health Sciences Centre Research Inc. — London, Ontario
- Stronach Regional Health Centre at Southlake — Newmarket, Ontario
- Lakeridge Health Oshawa — Oshawa, Ontario
- Ottawa Hospital Research Institute — Ottawa, Ontario
- Algoma District Cancer Program — Sault Ste. Marie, Ontario
- Niagara Health System — St. Catharines, Ontario
- St. Michael's Hospital — Toronto, Ontario
- St. Joseph's Health Centre — Toronto, Ontario
- Windsor Regional Cancer Centre — Windsor, Ontario
- CIUSSS de l'Est-de-I'lle-de-Montreal — Montreal, Quebec
- The Jewish General Hospital — Montreal, Quebec
- St. Mary's Hospital — Montreal, Quebec
- The Research Institute of the McGill University — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (613) 533-6430
Email: ahay@ctg.queensu.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.